Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome

Autoimmunity Reviews

Volumn 11, Issue 10, 2012, Pages 739-745

  Marie, I ^a   Josse, S ^a   Decaux, O ^b   Dominique, S ^c   Diot, E ^d   Landron, C ^e   Roblot, P ^e   Jouneau, S ^b   Hatron, P Y ^f   Tiev, K P ^g   Vittecoq, O ^c   Noel, D ^a   Mouthon, L ^h   Menard, J F ^c   Jouen, F ^a  

^a UNIVERSITÉ DE ROUEN   (France)

^b RENNES UNIVERSITY HOSPITAL   (France)

^c ROUEN UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY HOSPITAL OF TOURS   (France)

^e POITIERS UNIVERSITY HOSPITAL   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g HÔPITAL SAINT ANTOINE   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Anti Jo1 antibody; Anti PL12 antibody; Anti PL7 antibody; Antisynthetase syndrome; Cancer; Interstitial lung disease; Outcome; Prognostic factors

Indexed keywords

ANTIBODY; JO 1 ANTIBODY; PL 12 ANTIBODY; PL 7 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTISYNTHETASE SYNDROME; ARTHROPATHY; CANCER RISK; DISEASE SEVERITY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; MUSCLE WEAKNESS; MYALGIA; MYOSITIS; OUTCOME ASSESSMENT; PHENOTYPE; PREVALENCE; RECURRENT DISEASE; REVIEW; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ALANINE-TRNA LIGASE; ANTIBODIES, ANTINUCLEAR; HISTIDINE-TRNA LIGASE; HUMANS; MIDDLE AGED; MYOSITIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84864385547     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.01.006     Document Type: Review

References (59)

1. Dalakas M.C. Pathogenesis and therapies of immune-mediated myopathies. Autoimmun Rev 2011, 11:203-206.
2. Danieli M.G., Calcabrini L., Calabrese V., Marchetti A., Logullo F., Gabrielli A. Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimmun Rev 2009, 9:124-127.
3. Danieli M.G., Pettinari L., Moretti R., Logullo F., Gabrielli A. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev 2011, 10:144-149.
4. Defendenti C., Atzeni F., Spina M.F., Grosso S., Cereda A., Guercilena G., et al. Clinical and laboratory aspects of Ro/SSA-52 autoantibodies. Autoimmun Rev 2011, 10:150-154.
5. Ghillani P., André C., Toly C., Rouquette A.M., Bengoufa D., Nicaise P., et al. Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60 kDa antibodies: results of a multicentric study. Autoimmun Rev 2011, 10:509-513.
6. Ingegnoli F., Lubatti C., Boracchi P., Ingegnoli A., Zeni S., Meroni P.L. Interstitial lung disease outcomes by high-resolution computed tomography (HRCT) in Anti-Jo1 antibody-positive polymyositis patients: a single centre study and review of the literature. Autoimmun Rev 2011, doi:10.016/j.autrev.2011.09.007.
7. Marguerie C., Bunn C.C., Beynon H.L., Bernstein R.M., Hughes J.M., So A.K., et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 1990, 77:1019-1038.
8. Marie I., Guillevin L., Menard J.F., Hatron P.Y., Cherin P., Amoura Z. Hematological malignancy associated with polymyositis and dermatomyositis. Autoimmun Rev 2011, doi:10.016/j.autrev.2011.10.024.
9. Marie I., Mouthon L. Therapy of polymyositis and dermatomyositis. Autoimmun Rev 2011, 11:6-13.
10. Prieto S., Grau J.M. The geoepidemiology of autoimmune muscle disease. Autoimmun Rev 2010, 9:A330-A334.
11. Zampieri S., Valente M., Adami N., Biral D., Ghirardello A., Rampudda M.E., et al. Polymyositis, dermatomyositis and malignancy: a further intriguing link. Autoimmun Rev 2010, 9:449-453.
12. Marie I., Hatron P.Y., Dominique S., Cherin P., Mouthon L., Menard J.F. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum 2011, doi:10.016/j.semarthrit.2011.09.008.
13. Betteridge Z., Gunawardena H., North J., Slinn J., McHugh N. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology (Oxford) 2007, 46:1005-1008.
14. Marie I., Hatron P.Y., Dominique S., Cherin P., Mouthon L., Menard J.F. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 2011, 63:3439-3447.
15. Friedman A.W., Targoff I.N., Arnett F.C. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 1996, 26:459-467.
16. Hervier B., Uzunhan Y., Hachulla E., Benveniste O., Nunes H., Delaval P., et al. Antisynthetase syndrome positive for anti-threonyl-tRNA synthetase (anti-PL7) antibodies. Eur Respir J 2011, 37:714-717.
17. Katzap E., Barilla-LaBarca M.L., Marder G. Antisynthetase syndrome. Curr Rheumatol Rep 2011, 13:175-181.
18. Koreeda Y., Higashimoto I., Yamamoto M., Takahashi M., Kaji K., Fujimoto M., et al. Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. Intern Med 2010, 49(5):361-369.
19. Marie I., Hachulla E., Hatron P.Y., Hellot M.F., Levesque H., Courtois H., et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol 2001, 28:2230-2237.
20. Späth M., Schröder M., Schlotter-Weigel B., Walter M.C., Hautmann H., Leinsinger G., et al. The long-term outcome of anti-Jo-1-positive inflammatory myopathies. J Neurol Jul. 2004, 251(7):859-864.
21. Bohan A., Peter J.B. Polymyositis and dermatomyositis: first of two parts. N Engl J Med 1975, 292:344-347.
22. Bohan A., Peter J.B. Polymyositis and dermatomyositis: second of two parts. N Engl J Med 1975, 292:403-407.
23. Marie I., Lahaxe L., Benveniste O., Delavigne K., Adoue D., Mouthon L., et al. Long-term outcome of patients with polymyositis/dermatomyositis and anti-PM-Scl antibody. Br J Dermatol 2010, 162:337-344.
24. Quanjer P.H. Clinical respiratory physiology: standardized lung function testing: working party report: standardization of lung function tests. Bull Eur Physiopathol Respir 1983, 19(Suppl. 5):1-95.
25. Akira M., Hara H., Sakatani M. Interstitial lung disease in association with polymyositis-dermatomyositis: long-term follow-up CT evaluation in seven patients. Radiology 1999, 210:333-338.
26. Ikezoe J., Johkoh T., Kohno N., Takeuchi N., Ichikado K., Nakamura H. High-resolution CT findings of lung disease in patients with polymyositis and dermatomyositis. J Thorac Imaging 1996, 11:250-259.
27. Marie I., Hatron P.Y., Dominique S., Cherin P., Mouthon L., Menard J.F. Short term and long term outcome of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 2011, 63:3439-3447.
28. Mino M., Noma S., Taguchi Y., Tomii K., Kohri Y., Oida K. Pulmonary involvement in polymyositis and dermatomyositis: sequential evaluation with CT. AJR Am J Roentgenol 1997, 169:83-87.
29. Flaherty K.R., Thwaite E.L., Kazerooni E.A., Gross B.H., Toews G.B., Colby T.V., et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003, 58:143-148.
30. Schmidt S.L., Sundaram B., Flaherty K.R. Diagnosing fibrotic lung disease: when is high-resolution computed tomography sufficient to make a diagnosis of idiopathic pulmonary fibrosis?. Respirology 2009, 14:934-939.
31. Shin K.M., Lee K.S., Chung M.P., Han J., Bae Y.A., Kim T.S., et al. Prognostic determinants among clinical, thin-section CT, and histopathologic findings for fibrotic idiopathic interstitial pneumonias: tertiary hospital study. Radiology 2008, 249:328-337.
32. Warrick J.H., Bhalla M., Schabel S.I., Silver R.M. High resolution computed tomography in early scleroderma lung disease. J Rheumatol 1991, 18:1520-1528.
33. American Thoracic Society Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000, 161:646-664.
34. Bernstein R.M., Morgan S.H., Chapman J., Bunn C.C., Mathews M.B., Turner-Warwick M., et al. Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. Br Med J 1984, 289:151-152.
35. Bunn C.C., Bernstein R.M., Mathews M.B. Autoantibodies against alanyl-tRNA synthetase and tRNAAla coexist and are associated with myositis. J Exp Med 1986, 163:1281-1291.
36. Hirakata M. Autoantibodies to aminoacyl-tRNA synthetases. Intern Med 2005, 44:527-528.
37. Love L.A., Leff R.L., Fraser D.D., Targoff I.N., Dalakas M., Plotz P.H., et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991, 70:360-374.
38. Mathews M.B., Reichlin M., Hughes G.R., Bernstein R.M. Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody. J Exp Med 1984, 160:420-434.
39. Schmidt W.A., Wetzel W., Friedlander R., Lange R., Sörensen H.F., Lichey H.J., et al. Clinical and serological aspects of patients with anti-Jo-1 antibodies-an evolving spectrum of disease manifestations. Clin Rheumatol 2000, 19:371-377.
40. Targoff I.N., Arnett F.C. Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase). Am J Med 1990, 88:241-251.
41. Dugar M., Cox S., Limaye V., Blumbergs P., Roberts-Thomson P.J. Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies. Intern Med J 2011, 41:674-679.
42. Fischer A., Swigris J.J., du Bois R.M., Lynch D.A., Downey G.P., Cosgrove G.P., et al. Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respir Med 2009, 103:1719-1724.
43. Handa T., Nagai S., Kawabata D., Nagao T., Takemura M., Kitaichi M., et al. Long-term clinical course of a patient with anti PL-12 antibody accompanied by interstitial pneumonia and severe pulmonary hypertension. Intern Med 2005, 44:319-325.
44. Kalluri M., Sahn S.A., Oddis C.V. Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest 2009, 135:1550-1556.
45. Rubinowitz A.N., Moon M., Homer R. A 34-year-old man presenting with gradual onset of shortness of breath and interstitial lung disease. Chest 2008, 133:1041-1047.
46. Sato S., Hirakata M., Kuwana M., Nakamura K., Suwa A., Inada S., et al. Clinical characteristics of Japanese patients with anti-PL-7 (anti-threonyl-tRNA synthetase) autoantibodies. Clin Exp Rheumatol 2005, 23:609-615.
47. Yamasaki Y., Yamada H., Nozaki T., Akaogi J., Nichols C., Lyons R., et al. Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum 2006, 54:2004-2009.
48. Vancsa A., Gergely L., Ponyi A., Lakos G., Németh J., Szodoray P., et al. Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: relevance for clinical classification: retrospective study of 169 patients. Joint Bone Spine 2010, 77:125-130.
49. Marie I., Fournet P., Janvresse A., Levesque H., Courtois H. Periarticular calcifications and arthropathy as the first manifestation of polymyositis. Clin Exp Rheumatol 2003, 21:681-682.
50. Marie I., Kerleau J.M., Ducrotte P., Denis P., Maillot C., Levesque H., et al. Intravenous immunoglobulins and octreotide as treatment of intestinal pseudo-obstruction revealing a recurrence of polymyositis. Rheumatology (Oxford) 2001, 40:1072-1073.
51. Tweezer-Zaks N., Ben-Horin S., Schiby G., Bank I., Levi Y., Livneh A., et al. Severe gastrointestinal inflammation in adult dermatomyositis: characterization of a novel clinical association. Am J Med Sci 2006, 332:308-313.
52. Yoshifuji H., Fujii T., Kobayashi S., Imura Y., Fujita Y., Kawabata D., et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 2006, 39:233-241.
53. De Baets M.H. Insights in the autoimmunity of myasthenia gravis. Autoimmunity 2010, 43:341-343.
54. Meyer A., Levy Y. Geoepidemiology of myasthenia gravis. Autoimmun Rev 2010, 9:A383-A386. Erratum in: Autoimmun Rev 2011;10:811.
55. Buchbinder R., Forbes A., Hall S., Dennett X., Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 2001, 134:1087-1095.
56. Chinoy H., Fertig N., Oddis C.V., Ollier W.E., Cooper R.G. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007, 66:1345-1349.
57. Legault D., McDermott J., Crous-Tsanaclis A.M., Boire G. Cancer-associated myositis in the presence of anti-Jo1 autoantibodies and the antisynthetase syndrome. J Rheumatol 2008, 35:169-171.
58. Rozelle A., Trieu S., Chung L. Malignancy in the setting of the anti-synthetase syndrome. J Clin Rheumatol 2008, 14:285-288.
59. Watkins J., Farzaneh-Far R., Tahir H., Wykes F., Studdy P.R., Beynon H.L. Jo-1 syndrome with associated poorly differentiated adenocarcinoma. Rheumatology (Oxford) 2004, 43:389-390.